Moderna, BioNTech rise as vaccine advisory panel backs off mRNA vaccine threat

 

• Stocks focused on developing mRNA vaccines, including Moderna (MRNA) and BioNTech (BNTX), are higher in Wednesday trading following a report that an HHS vaccines advisory committee is walking back a possible plan to stop recommending mRNA jabs.
• Two individuals with knowledge of the situation told The Washington Post that the Advisory Committee on Immunization Practices has backed off their prior threat.
• The two companies developed mRNA COVID-19 vaccines that were widely administered during the pandemic. BioNTech's shot was developed with Pfizer (PFE).
• Several ACIP members had said that DNA elements in the vaccines were potentially harmful.

https://www.msn.com/en-us/health/other/moderna-biontech-rise-as-vaccine-advisory-panel-backs-off-mrna-vaccine-threat/ar-AA1YproD